Sharon Rosenzweig-Lipson

Dr. Sharon Rosenzweig-Lipson brings scientific depth along with strong leadership and critical strategic thinking to her role as Interim CSO at Life Biosciences. Sharon is also the owner of IVS Consulting. She provides expertise in screening strategies, in vivo models, translation, and clinical development strategy with more than 30 years of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry. Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer. She has successfully led teams from the exploratory phase through to a successful Phase 2 proof-of-concept in schizophrenia and is currently completing a Phase 2B trial in mild cognitive impairment due to Alzheimer’s Disease.

Dr. Rosenzweig-Lipson earned her BA in biological basis of behavior from the University of Pennsylvania and her PhD in behavioral neuroscience from Harvard University.